Britni Rabbeitt
Psychiatric/Mental Health · Fairhope, ALNPI 1144977984
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.7% of the total. Reporting peaked in 2023 at $2,154 and has fallen 61.8% since, to $823 in 2025.
Across 339 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$918
- AbbVie$692
- Teva Pharmaceuticals USA, Inc.$555
- Alkermes, Inc.$491
- Neurocrine Biosciences, Inc.$478
- plus $2K from 12 others
What the payments were for
- Food & beverage$6,673100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,649 |
| Otsuka America Pharmaceutical, Inc. | 45 | $918 |
| AbbVie | 57 | $692 |
| Teva Pharmaceuticals USA, Inc. | 29 | $555 |
| Alkermes, Inc. | 20 | $491 |
| Neurocrine Biosciences, Inc. | 18 | $478 |
| Supernus Pharmaceuticals, Inc. | 20 | $411 |
| Corium, LLC | 22 | $361 |
| Lundbeck LLC | 19 | $327 |
| Axsome Therapeutics, Inc. | 7 | $231 |
| Johnson & Johnson | 13 | $230 |
| Indivior Inc. | 4 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$476
- CAPLYTA$251
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- QELBREE$120
- VRAYLAR$114
How this compares
$6,673 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 75 | $226,028 |
| IngrezzaValbenazine Tosylate | 14 | $118,067 |
| Abilify AsimtufiiAripiprazole | 20 | $102,771 |
| VraylarCariprazine Hcl | 53 | $79,326 |
| Abilify MaintenaAripiprazole | 29 | $77,422 |
| RexultiBrexpiprazole | 46 | $74,467 |
| CaplytaLumateperone Tosylate | 20 | $31,833 |
| Lurasidone Hcl | 33 | $5,417 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 43 | $3,082 |
| Doxepin Hcl | 31 | $2,605 |
| Buspirone Hcl | 125 | $2,109 |
| Duloxetine Hcl | 84 | $2,078 |
| Hydroxyzine Pamoate | 126 | $1,780 |
| Clozapine | 17 | $1,604 |
| Quetiapine Fumarate | 134 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $918 | $254,66195 claims |
| Johnson & JohnsonInvega Sustenna | $230 | $226,02875 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $478 | $118,06714 claims |
| AbbVieVraylar | $692 | $79,32653 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,649 | $31,83320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Fairhope
- Margaret KellarFairhope$7K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Anthony PhillipsHelena$15K
- Ian KinzerHuntsville$15K
- Latisha AliHoover$15K
- Taylor BarrettGadsden$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.